Browsing by Person "Dukatz, R."

Type the first few letters and click on the Browse button
Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1)
    (2022) Berling-Ernst, Anika; Yahiaoui-Doktor, Maryam; Kiechle, Marion; Engel, Christoph; Lammert, Jacqueline; Grill, Sabine; Dukatz, R.; Rhiem, Kerstin; Baumann, F. T.; Bischoff, Stephan C.; Erickson, N.; Schmidt, Thorsten; Niederberger, Uwe; Siniatchkin, M.; Halle, Martin; Berling-Ernst, A.; Department of Prevention and Sports Medicine, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich (TUM), Munich, Germany; Yahiaoui-Doktor, M.; Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany; Kiechle, M.; Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, University Hospital Rechts der Isar, Technical University of Munich (TUM), Munich, Germany; Engel, C.; Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany; Lammert, J.; Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, University Hospital Rechts der Isar, Technical University of Munich (TUM), Munich, Germany; Grill, S.; Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, University Hospital Rechts der Isar, Technical University of Munich (TUM), Munich, Germany; Dukatz, R.; Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, University Hospital Rechts der Isar, Technical University of Munich (TUM), Munich, Germany; Rhiem, K.; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Baumann, F. T.; Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany; Bischoff, S. C.; Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany; Erickson, N.; Comprehensive Cancer Center Ludwig Maximillian University (CCC LMU), University of Munich Clinic, Munich, Germany; Schmidt, T.; University Cancer Center Schleswig-Holstein (UCCSH), Kiel, Germany; Niederberger, U.; Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel, Germany; Siniatchkin, M.; Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel, Germany; Halle, M.; DZHK (German Centre for Cardiovascular Research), Munich, Germany
    Physical activity (PA) helps prevention and aftercare of sporadic breast cancer (BC), cardiopulmonary fitness (CPF) being an age-independent predictor of tumor-specific mortality. Therefore, we wanted to identify predictors of CPF (represented by peak oxygen uptake: VO2peak) in BRCA1/2 mutation carriers whose risk of developing BC is high. We used cross-sectional data from 68 BRCA1/2 germline mutation carrying women participating in the randomized, prospective, controlled clinical study LIBRE-1. Assessments included cardiopulmonary exercise testing, medical and lifestyle history plus socioeconomic status. Additionally, the participants completed a psychological questionnaire regarding their attitude, subjective norms, perceived behavior control and intention towards PA. A multivariate logistic regression model was used to identify predictors for participants reaching their age- and sex-adjusted VO2peak reference values. 22 participants (median age: 40 years, interquartile range (IQR) 33–46) were cancer-unaffected and 46 cancer-affected (median age: 44 years, IQR 35–50). The strongest predictor for reaching the reference VO2peak value was attitude towards PA (Odds Ratio 3.0; 95% Confidence Interval 1.3–8.4; p = 0.021). None of the other predictors showed a significant association. A positive attitude towards PA seems to be associated with VO2peak, which should be considered in developing therapeutic and preventive strategies.Trial registrations: NCT02087592; DRKS00005736.